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META-ANALYSIS
A Systematic Review of Mortality in Schizophrenia
Is the Differential Mortality Gap Worsening Over Time?
Sukanta Saha, MSc, MCN; David Chant, PhD; John McGrath, MD, PhD, FRANZCP
Context: Despite improvements in mental health ser-
vices in recent decades, it is unclear whether the risk of
mortality in schizophrenia has changed over time.
Objective: To explore the distribution of standardized
mortality ratios (SMRs) for people with schizophrenia.
Data Sources: Broad search terms were used in
MEDLINE, PsychINFO, Web of Science, and Google
Scholar to identify all studies that investigated mortality
in schizophrenia, published between January 1, 1980, and
January 31, 2006. References were also identified from
review articles, reference lists, and communication with
authors.
Study Selection: Population-based studies that re-
ported primary data on deaths in people with schizo-
phrenia.
Data Extraction: Operationalized criteria were used to
extract key study features and mortality data.
Data Synthesis:We examined the distribution of SMRs
and pooled selected estimates using random-effects
meta-analysis. We identified 37 articles drawn from 25
different nations. The median SMR for all persons for
all-cause mortality was 2.58 (10%-90% quantile, 1.18-
5.76), with a corresponding random-effects pooled SMR
of 2.50 (95% confidence interval, 2.18-2.43). No sex dif-
ferencewas detected. Suicidewas associatedwith the high-
est SMR (12.86); however, most of the major causes-of-
death categories were found to be elevated in people with
schizophrenia. The SMRs for all-causemortality have in-
creased during recent decades (P=.03).
Conclusions:With respect tomortality, a substantial gap
exists between the health of people with schizophrenia
and the general community. This differential mortality
gap has worsened in recent decades. In light of the po-
tential for second-generation antipsychotic medications
to further adversely influence mortality rates in the de-
cades to come, optimizing the general health of people
with schizophrenia warrants urgent attention.
Arch Gen Psychiatry. 2007;64(10):1123-1131
I T IS NOW WIDELY ACKNOWL-edged that schizophrenia con-tributes substantially to the globalburden of disease.1,2 It is alsowellknown that schizophrenia is
associated with elevated suicide rates.3
Less widely appreciated is the fact that
people with schizophrenia are at in-
creased risk for premature death associ-
ated with comorbid somatic conditions.4
Apart fromadverse effects related tomedi-
cation, schizophrenia can trigger a cas-
cade of socioeconomic and lifestyle fac-
tors that, in turn, can translate into adverse
physical health outcomes. These comor-
bid physical conditions contribute to in-
creasedmortality risks amongpeoplewith
schizophrenia.
The association between severe men-
tal illness and increasedmortality rates has
long been recognized.5With respect to the
group of disorders now labeled schizo-
phrenia, increased mortality rates have
been the object of scrutiny since the early
20th century.6-8 The quality of research on
this topic has improved greatly in recent
decades, with access to larger, better-
characterized samples and the availabil-
ity of high-quality mortality data for the
general population. Access to these data
allows the calculation of the standard-
ized mortality ratio (SMR), which com-
paresmortality in peoplewith schizophre-
nia vs the general population. The SMRs
are calculated by dividing the observed
mortality rates in a given population (eg,
the number of deaths in a group of indi-
viduals with schizophrenia) by the ex-
pected mortality rates in that same group
as predicted by age- and sex-specific mor-
tality rates for a standard population. Thus,
an SMR of 2.0 would indicate that people
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with schizophrenia are twice as likely to die compared
with the general population. The SMRs can be calcu-
lated for overall mortality (all-cause) or for more spe-
cific, widely used categories (eg, cancer, cardiovascular
disease, endocrine disorders, or suicide).
In recent years, several scholarly reviews4,9-11 have noted
highermortality in schizophrenia comparedwith the gen-
eral population.Ameta-analysis,4 based on18 studies pub-
lished between 1969 and 1996, reported an all-cause SMR
for people with schizophrenia of 1.51. Another meta-
analysis,11 based on 20 studies published between 1973
and 1995, reported a similar SMR for people with schizo-
phrenia (1.57). Although these 2 systematic reviews
agreed on the size of the pooled SMR associated with
schizophrenia, there were discrepancies in the sex dif-
ference of overall mortality ratios. Brown4 found a small
but significant male excess in the overall mortality ra-
tio, whereas other studies12,13 reported either no sex dif-
ference11 or higher mortality ratios in females compared
with males.
In collating data from different sites, systematic re-
viewers need to appreciate the structure of the underly-
ing data. In light of the differing population age struc-
ture and disease profile among sites,1,14 we would expect
substantial variation in mortality ratios among sites. For
example, one would predict that SMRs for people with
schizophrenia would differ between developed and de-
veloping nations, where the profiles of disease and the
access to services vary markedly.
Because of the increased focus on mental health care
seen in many countries during the last few decades, one
might predict that SMRs associated with disorders such
as schizophrenia should be decreasing over time.15,16 How-
ever, several authors have suggested that SMRs in schizo-
phrenia have been increasing during recent decades. For
example, Osby et al17 found a linear increasing trend of
mortality during 5-year periods from1976 to 1995 among
people with schizophrenia. Themeta-analysis by Brown4
also reported significantly higher mortality in the 1980s
comparedwith the 1970s.Deinstitutionalizationmayhave
influenced recent secular changes in mortality rates in
schizophrenia. Although deinstitutionalization started in
the 1950s, findings on its relationship to mortality have
been inconsistent.10,11,18
The aims of this study were to undertake a system-
atic review of mortality in schizophrenia and to exam-
ine a limited number of planned sensitivity analyses. In
keeping with our previous systematic review of the in-
cidence19 and prevalence20 of schizophrenia and consid-
ering that variability is to be expected in systematic re-
views of SMRs,4,21 we sought to preserve the expected
variation in the data rather than to focus only on pooled
values derived from meta-analysis. Thus, for the main
analyses, we present distributions of mortality esti-
mates with measures of central tendency (eg, median or
means) and quantiles (10% and 90% quantiles). On the
basis of all-cause SMR, we predicted that the SMRs of
males and females would not differ significantly.We also
predicted that SMRs from the developedworldwould dif-
fer from those from the developing world (nondirec-
tional hypothesis). We wished to explore the impact of
study quality on SMRs.With the assumption that higher-
quality studies would be more likely to identify deaths
in schizophrenia, we predicted that SMRs derived from
such studies would be higher compared with those from
lower-quality studies. On the basis of previous system-
atic reviews and commentaries, we predicted that SMRs
would increase over time.
METHODS
DATA SOURCES
Mostmortality studies are based on record linkage. People with
schizophrenia are identified via psychiatric case registers and
then subsequently linked to registers of cause of death. Some
studies13,22 report mortality ratios based on hospital inpatient
cohorts. Other studies23,24 have used community-based fol-
low-up data for people with schizophrenia who are first iden-
tified through community surveys and then followed up for ex-
tended periods.
IDENTIFICATION OF STUDIES
Guidelines outlined by theMeta-analysis of Observational Stud-
ies in Epidemiology25 were followed to identify and collatemor-
tality studies. The broad search string of (schizo* or psych*)
and (mortality or outcome or follow-up) was used inMEDLINE,
PsychINFO, Web of Science, and Google Scholar to identify
all research studies that investigated mortality in schizophre-
nia. Potentially relevant articles (in all languages) were ac-
cessed to review the full text. Citations from significant ar-
ticles and review articles were scrutinized to locate additional
relevant articles, book chapters, and conference papers. TheWeb
of Science Cited Reference Search system was also used to lo-
cate relevant articles. Finally, letters or e-mails were sent to the
senior authors of articles that met the inclusion criteria. These
authors were provided with an interim list of included studies
and asked to nominate missing studies.
INCLUSION AND EXCLUSION RULES
Studies were included if they met all the following criteria: (1)
published and/or available between January 1, 1980, and Janu-
ary 31, 2006, (2) reported deaths in people with schizophre-
nia as diagnosed by any criteria, (3) studied a population 15
years and older, (4) reported primary data on all-cause mor-
tality and/or cause-specific mortality, and (5) reported SMRs
and/or data on observed and expected deaths sufficient to cal-
culate SMRs. Studies were excluded if they (1) involved people
with a diagnosis other than schizophrenia (ie, studies that re-
ported on broader categories of psychosis were excluded), (2)
reported duplicate data, (3) reported SMRs solely attributable
to suicide (this was the focus of a recent systematic review and
meta-analysis3), and (4) reportedmortality in subgroups of the
population (eg, homeless people,26 twins,27 and those in-
volved in clinical trials).
DATA ABSTRACTION
Once a study was included, data were extracted and entered
into a 3-level, normalized database that included study-level
variables (eg, authors, year of publication, and site), middle-
level variables (eg, age group, recruitment duration, case-
findingmethod, and diagnostic criteria), and estimate-level vari-
ables (eg, general and specific-cause SMRs for all persons,males,
or females). Two or more of the authors checked all data used
in the analysis. When disagreements arose, these were re-
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solved by consensus. If required, we contacted the original au-
thors for clarification of issues. The full data set is available from
the authors (www.qcmhr.uq.edu.au/epi).
To assess the impact of overall quality of the distribution
of SMRs, we devised a quality score. On the basis of operation-
alized criteria, this score rewarded studies that (1) used supe-
rior research design features (eg, more thorough case ascer-
tainment, published diagnostic criteria, methods to confirm
diagnosis, and longer periods of follow-up) and (2) provided
comprehensive reporting of the study results (eg, provision of
numerator, denominator, SMRs, details of subject attrition, and
description of the completeness of the data source). Full de-
tails of the quality score used in this review are available from
the authors (www.qcmhr.uq.edu.au/epi).
In systematic reviews, it is important to avoid double count-
ing of the index variable (deaths) by the same or different stud-
ies. Thus, a key feature of this review is the application of se-
quential filters to identify discretemortality estimates.Weapplied
a similar sorting algorithm to that used in our previous re-
views of schizophrenia.19,20 Briefly, themortality estimates were
sorted into different causes of death. Study-level and middle-
level filters were applied to isolate data from multiple studies
that overlapped in both time and place. The third filter was used
to select 1 representativemortality estimate for inclusion in the
cumulative distribution using the “most informative” rule. For
example, if 1 study presented multiple overlapping ratios, the
ratios based on the largest sample were preferred (ie, the wid-
est age range was preferred over narrower age strata).
The highest-order (andmost reliable) category of death, all-
cause mortality, can be further subdivided according to rules
such as those codified by the International Classification of Dis-
eases, Ninth Revision (ICD-9).28 Almost all included studies in
this reviewwere coded with the ICD-9. Although death can re-
sult from the combination of many different health problems,
in circumstances in which several codes may be suitable, em-
phasis is given to the underlying cause of death. More specific
causes of death can be allocated to categories according to or-
gan systems (eg, cardiovascular or gastrointestinal) or nature
of disease (eg, cancers are coded together). Apart from codes
for these specific domains, studies occasionally report SMRs
for middle-level categories such as all-unnatural (ICD-9 codes
E800-E999) (which includes codes for suicide, accident, and
homicide) and all-natural (ICD-9 codes 001-799; the remain-
der from all-cause when all-unnatural cause is excluded).
The SMRs were extracted from the publications or calcu-
lated by dividing the sum of observed deaths by the sum of ex-
pected deaths (when sufficient data were available to calculate
these). The distributions of SMRs were assessed in cumulative
plots, with every SMR contributing to the distribution. The dis-
tribution of the data was assessed in rank order for SMRs (low-
est to highest ranks) with the cumulative percentage of SMRs
shown on the vertical axis. Key features of these distributions
are presented (eg, median, mean, geometricmean, standard de-
viation, and quantiles at 10%, 25%, 50%, 75%, and 90%).
For all-cause death, we were often able to extract data on
case fatality rate (CFR). The CFR is calculated by dividing the
number of deaths in people with schizophrenia during a cer-
tain period by the number of people with that disorder at the
beginning of the period. An annualized CFRwas derived to al-
low comparisons among studies of different durations.14
In keeping with definitions from our previous systematic
reviews of schizophrenia,20,29 we divided studies according to
the per capita gross national product of the study site (based
on 2004 data)30 and used a standard World Bank definition of
country status31: (1) least developed countries,mean income
of less than US $2995; (2) emerging economy countries,mean
income betweenUS $2995 and $9266; and (3) developed coun-
tries,mean income of greater than US $9266.
To assess secular trends, we usedmeta-regression to exam-
ine the relationship between the midpoint of the follow-up pe-
riod and all-cause SMR for persons. Study quality scores were
divided into tertiles, and the distribution of all-cause SMR for
persons were compared according to these 3 levels.
We performed statistical analyses for the test of signifi-
cance between distributions of different SMRs. These analyses
take into account (1) the need to control for within-study varia-
tion (estimates drawn from the same study tend to bemore alike
than SMRs drawn from different studies) and (2) the use of a
log transformation to analyze distributions that are often posi-
tively skewed. Analyseswere performedwith SAS statistical soft-
ware, version 9.2 (SAS Institute Inc, Cary, North Carolina).
We also undertook a secondary analysis based on conven-
tional meta-analytic techniques. Because SMRs are known to
vary widely among sites because of population and disease fre-
quency differences, we adopted a random-effects model to es-
timate a pooled SMR for all-causemortality for persons.21When
necessary, 95% confidence intervals (CIs) were generated ac-
cording to the formula detailed by Rothman and Greenland.21
Heterogeneity among the studies was tested using the Coch-
ran heterogeneity statistic.32 Apart from the specific analyses
related to sex differences, we restricted the analyses to per-
sons to limit the number of planned comparisons. The fund-
ing source played no part in the design, analyses, writing, or
submission of this study.
RESULTS
The electronic search identified 1726 articles, whereas
manual reference checking identified an additional 26
references.We received responses from 16 authors, who
provided an additional 11 references. Four articles from
languages other than English were included after trans-
lation. Eleven studies33-43were excludedbecause they com-
pletely overlapped with other included studies. Further
details of the results of the search strategy and key fea-
tures of the included studies are available from the au-
thors (www.qcmhr.uq.edu.au/epi).
Thesystematic reviewidentified37studies9,12,13,18,22-24,44-73
that provided data on 561 SMRs for different causes
of deaths drawn from 25 different countries: Australia
(n=2),59,68 Brazil (n=1),61 Bulgaria (n=1),53 Canada
(n=3),50,51,65 China (n=1),53 Columbia (n=1),53 CzechRe-
public (n=1),53 Denmark (n=2),63,64 Finland (n=3),18,22,23
France (n=2),46,48 Germany (n=1),57 HongKong (n=1),53
India (n=2),12,53 Indonesia (n=1),58 Ireland (n=2)53,62
Israel (n=1),73 Italy (n=2),60,67 Japan (n=3),53,69,71 Norway
(n=1),52 Russia (n=1),53 Sweden (n=2),9,66 Taiwan
(n=1),49 the Netherlands (n=1),13 the United Kingdom
(n=5),44,47,53,54,56 and the United States (n=6).24,45,53,55,70,72
The SMRs were based on an estimated total of 22 296
discrete deaths. Thirty-seven studies9,12,13,18,22-24,44-73 pro-
vided SMRs for all-cause mortality for either all per-
sons, males, or females.
Figure1 shows the distribution for all-cause SMRs for
all persons,males, and females. Themedian all-cause SMR
for all persons (based on 38 SMRs) was 2.58, with 10%
and 90% quantiles ranging from 1.18 to 5.76 (Table 1).
In other words, people with schizophrenia had 2.5 times
the risk of dying compared with the general population,
and the central 80%of all SMRs varied over a 4-fold range.
Themedian annualized all-cause CFR for all persons was
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95.4 per 10 000 population, with 10% and 90% quantiles
ranging from 57.2 to 301.7 (5-fold range).
Themedian all-cause SMR formales (3.02)was slightly
higher than females (2.37); however, these 2 distribu-
tions were not statistically significantly different
(F1,18=0.0003; P=.99). For all persons, the median SMR
for natural causes of death was 2.41, and the 10% and
90% quantiles ranged from 0.99 to 4.10 (Table 1). El-
evated median SMRs were found in all of the specific
causes of death apart from cerebrovascular diseases.
Seven studies18,47,49,51,56,65,66 published data for the sum-
mary category of unnatural causes of death for all per-
sons, males, or females. Table 1 gives the distributions
of SMRs for unnatural causes of death. Peoplewith schizo-
phrenia had 12 times the risk of dying of suicide com-
pared with the general population (median SMR, 12.86).
Twenty-two studies* were identified that contrib-
uted 28 SMRs for developed countries, 3 studies53,58,61 con-
tributed 6 SMRs for emerging economy countries, and 1
study53 contributed 4 SMRs for least developed coun-
tries. When divided according to this criterion, the all-
cause SMR distributions were not significantly different
(F2,34=0.30; P=.74); the median all-cause SMRs for least
developed, emerging economy, and developed coun-
tries were 2.02, 2.19, and 2.79, respectively (Table 2).
When the all-cause SMRs for all persons were di-
vided into study quality score tertiles, no significant dif-
ferences were found between SMR distributions
(F2,24=0.61; P=.55). On the basis of follow-up periods,
we identified 8 studies24,45,51,54,55,63,71,72 with SMRs from the
1970s, 10 studies47,53,57-60,65-67,73 with SMRs from the 1980s,
and7 studies22,46,48,53,61,62,68 with SMRs from the 1990s.Con-
cerning secular change, meta-regression confirmed a sig-
nificant positive association between the follow-up pe-
riodmidpoint year and all-cause SMR (slope coefficient,
0.06; 95% CI, 0.01-0.11; z=2.21; P=.03). The median
SMRs for the 1970s, 1980s, and 1990s were 1.84, 2.98,
and 3.20, respectively. ConcerningCFRs, themedian rates
per 10 000 population (all-cause mortality) were 162.2,
95.4, and 108.3 for the 1970s, 1980s, and 1990s, respec-
tively. The CFRs for the 3 decades were not statistically
significantly different (F2,23=0.38; P=.38).
The 38 studies that report all-cause SMRs for all per-
sons are shown in a traditional forest plot with a pooled
estimate based on a random-effects model in Figure 2.
Using traditional meta-analytic techniques, we found that
thepooled random-effects all-causeSMR(basedon37SMRs
with finite standard errors) for all persons was 2.50 (95%
CI, 2.18-2.83). The CochranQ test found amarginally ac-
ceptable level of heterogeneity (Q36=50.72;P=.06).Weun-
dertook several post hoc analyses to explore potential
sources of variation (eg, published vs unpublished diag-
nostic criteria, cohorts based on first-episode patients vs
all patients, cohorts based on inpatient and/or outpatient
samples, sites clustered according to World Health Orga-
nization regions, and SMRs attributable to suicide sorted
by decade). However, none of the post hoc comparisons
resulted in significantly different SMR distributions (data
not shown).
COMMENT
People with schizophrenia have a substantially in-
creased risk of death compared with the general popu-
lation. Overall, people with schizophrenia have 2.5 times
the risk of dying. This reviewwas able to extract data from
37 studies that were conducted in 25 countries. As pre-
dicted, the distribution of all-cause SMRs showed promi-
nent variability.
Confirming the hypothesis that the relative mortality
risk associatedwith schizophrenia is increasing, we found
that SMRs have increased in a linear fashion during the
3 decades examined in this study. This finding is con-
sistent with earlier studies.4,17 Considering that (1) CFRs
for schizophrenia did not significantly differ among the
decades and (2) age-standardizedmortality rates are gen-
erally decreasing inmost nations,74-76 these findings sug-
gest that people with schizophrenia have not fully ben-
efited from the improvements in health outcomes available
to the general population. The SMRs are ratio measures
and thus reflect differential mortality. If mortality rates
in the general population decrease over time at a faster
rate than those for people with schizophrenia, then SMRs
for peoplewith schizophreniawill increase over time. The
evidence from the current study suggests that this dif-
ferential mortality gap has widened over time.
Mental health services have advanced in many parts
of the world during the past few decades. Apart from a
different mix of community-based care, the introduc-
tion of the second-generation antipsychotic medica-
tions in the early 1990s was initially found to be associ-
ated with better quality of life and reduced risk of
relapse.77-79 More recent trials have questioned the clini-
cal superiority of second-generation antipsychotic medi-
cation,80,81 and concern is nowwidespread about the ad-
verse effects associated with these medications.82 In
particular, compared with typical antipsychotics, sev-
eral of the second-generation antipsychotics are more
likely to cause weight gain and metabolic syndrome.83
Because the metabolic syndrome is associated with a 2-



























Figure 1. Cumulative plots of standardized mortality ratios (SMRs) for
all-cause mortality associated with schizophrenia by sex.
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 64 (NO. 10), OCT 2007 WWW.ARCHGENPSYCHIATRY.COM
1126
©2007 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
to 3-fold increase in cardiovascularmortality and a 2-fold
increase in all-cause mortality,84 these adverse effects
would be expected to contribute to even higher SMRs in
the next few decades.85,86 Unfortunately, we are unable
to explore the role of atypical medications as a contrib-
uting factor for the increasing SMRs associated with
schizophrenia (eg, deaths related to clozapine-induced
agranulocytosis or deaths related to atypical antipsychotic-
induced weight gain). Adverse health outcomes associ-
ated with weight gain and/or metabolic syndrome (eg,
myocardial infarction, cerebrovascular accidents, or can-
cer)may take decades to fully emerge. Thus, it seems likely
that studies undertaken in the 1990s (ie, the most re-
cent studies included in this review) would capture only
a small fraction of the eventual burden of mortality as-
sociated with the adverse effect profile of the second-
generation antipsychotic medications. In light of the ris-
ing secular trends in SMRs already identified by this
review, the prospect of further increases inmortality risks
for schizophrenia is alarming.
In keeping with the findings of Harris and Barra-
clough11 and Simpson,10 we found no significant sex dif-
ference in all-cause SMRs. Thus, although many well-
documented sex differences exist in the epidemiological
features of schizophrenia,19,87,88 the increased risk ofmor-
tality associated with schizophrenia affects men and
women equally.
Of the specific-cause SMRs, suicidewas associatedwith
the highest estimate: 12 times greater than expected from
the general population. In keeping with previous re-
views, the SMRs associated with many different types of
natural causes of death were elevated in people with
schizophrenia. Curiously, the category neoplastic disor-
der had one of the lowest median SMRs (1.37). Al-
though the median was still greater than 1, several rec-
ord linkage studies89 have suggested that cancers may be
significantly less prevalent in people with schizophre-
nia. The current review examines onlymortality, and stud-
ies that examine morbidity would be better able to ex-
plore this issue.90
We found no significant difference in SMRs among
siteswhen sorted by economic status. However, thismeta-
analysis identified just 3 studies53,58,61 that provided dis-
crete SMRs from the least developed and emerging
economy countries; thus, caution should be exercised in
the interpretation of this finding. Furthermore, a single
derived variablewas used to define economic status,which
was applied at the ecological level.
What factors have contributed to the differential mor-
tality risk associated with schizophrenia? Many demo-







Mean10% 25% Median 75% 90%
All-Cause and Middle-Level Categories
All-cause (ICD-9 codes 001-799/E800-E999) 38 1.18 1.87 2.58 3.64 5.76 2.98 (1.75) 2.68
All-natural cause (ICD-9 codes 001-799) 6 0.99 1.04 2.41 2.90 4.10 2.31 (1.18) 2.03
All-unnatural cause (ICD-9 codes E800-E999) 3 5.56 5.56 7.50 12.73 12.73 8.60 (3.71) 8.10
Natural Causes, Cause Specific
Cardiovascular diseases (ICD-9 codes 390-429) 7 1.11 1.40 1.79 2.49 3.60 2.01 (0.83) 1.88
Cerebrovascular diseases (ICD-9 codes 430-438) 3 0.61 0.61 0.69 1.30 1.30 0.87 (0.38) 0.82
Digestive diseases (ICD-9 codes 520-579) 5 1.79 2.24 2.38 2.50 17.50 5.28 (6.84) 3.34
Endocrine diseases (ICD-9 codes 250-259) 3 2.20 2.20 2.63 11.66 11.66 5.50 (5.34) 4.07
Infectious diseases (ICD-9 codes 001-139) 3 1.60 1.60 4.29 7.80 7.80 4.56 (3.11) 3.77
Genitourinary diseases (ICD-9 codes 580-629) 3 1.54 1.54 3.70 4.29 4.29 3.18 (1.45) 2.90
Neoplastic diseases (ICD-9 codes 140-239) 7 0.71 1.00 1.37 2.01 2.40 1.44 (0.60) 1.33
Nervous diseases (ICD-9 codes 345-349) 4 1.60 1.95 4.22 6.57 7.00 4.26 (2.70) 3.55
Respiratory diseases (ICD-9 codes 460-519) 6 2.20 2.39 3.19 3.80 9.30 4.01 (2.66) 3.51
Other diseases (ICD-9 codes 1-389/630-799) 3 1.45 1.45 2.00 3.40 3.40 2.28 (1.01) 2.14
Unnatural Causes, Cause Specific
Accident (ICD-9 codes E800-E949) 6 1.20 1.63 1.73 5.10 8.40 3.30 (2.88) 2.51
Suicide (ICD-9 codes E950-E959) 10 0.66 5.90 12.86 21.43 174.25 43.47 (95.11) 16.13
Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision (ICD-9); SMRs, standardized mortality ratios.







Mean10% 25% Median 75% 90%
Least developed countries 4 1.88 1.89 2.02 2.75 3.36 2.32 (0.70) 2.25
Emerging economy countries 6 1.04 1.31 2.19 5.98 8.43 3.52 (3.03) 2.57
Developed countries 28 1.18 1.97 2.79 3.74 5.69 2.96 (1.52) 2.77
Abbreviation: SMRs, standardized mortality ratios.
aF2,34 = 0.30; P = .74.
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graphic, clinical, political, and cultural factors mediate
pathways and barriers to health care in general (eg, avail-
ability of services, stigma, and disease profiles).91 With
respect to schizophrenia, the onset of the illness can re-
sult in a cascade of unhealthy lifestyle factors that el-
evate the risk of various somatic diseases and conse-
quently increase the risk of death. People with
schizophrenia are thought to be less inclined to seekhealth
care, to consume less medical care, to engage in high-
risk behaviors, and to be less compliant with their treat-
ments.82,90,92 However, in addition to factors that oper-
ate on the pathway to care, schizophrenia and its
associated comorbid somatic conditions may be down-
stream expressions of common genetic or environmen-
tal factors.92,93 For example, it is feasible that polymor-
phisms in genes may increase the susceptibility to both
schizophrenia and diabetes94 or that de novo germline
mutations across many generations could result in an in-
creased risk of schizophrenia95 and a wide range of ad-
verse health outcomes. Prenatal nutritional disruptions
may equally affect brain development and general meta-
bolic functioning.96,97 Although the current review can-
not address these issues directly, the worsening SMRs as-
sociated with schizophrenia noted in recent decades
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Figure 2. Forest plot of standardized mortality ratios (SMRs) for all-cause mortality in people with schizophrenia. Individual SMRs and the pooled estimate are
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suggest that this already disadvantaged group is not ben-
efiting from the improved health of the community in
an equitable fashion. A systematic approach to monitor-
ing and treating the physical health needs of people with
schizophrenia is clearly warranted.98
Several important caveats to this review should be
noted. Publication bias is always an issue in systematic
reviews.We endeavored to address this by obtaining data
from all available sources, including those from elec-
tronic databases, citations and authors, and publica-
tions in languages other than English. Factors such as
the reliability of psychiatric diagnoses and admission prac-
tices (between sites and across time) could contribute to
the variability identified in this systematic review. The
reliability of the categorization of cause of death is also
a cause for concern. With respect to specific-cause mor-
tality, changes in the coding rules for the ICD-9 and be-
tween-site variability in the application of these rules also
need to be taken into account.99,100 However, these is-
sues do not affect all-cause SMRs (which were used for
themain analyses in this review). The current study found
a higher all-cause SMR (median SMR, 2.58; pooledmeta-
analysis SMR, 2.50) compared with the 2 previous re-
views, which reported all-cause SMRs of 1.514 and 1.57.11
The 2 previous systematic reviews were based on stud-
ies published before 199511 and 19964 comparedwith the
current systematic review, which included 18 addi-
tional studies published after 1995.
In conclusion, compared with the general popula-
tion, people with schizophrenia have a 2- to 3-fold in-
creased risk of dying. Suicide contributes to the in-
creasedmortality associatedwith schizophrenia; however,
people with schizophrenia have increasedmortality risks
attributable to a wide range of somatic conditions. The
increased mortality risk affects both sexes equally. Sub-
stantial variation occurs in all-cause SMRs among sites.
In recent decades, the differential mortality gap associ-
ated with schizophrenia has been increasing. It is
sobering to reflect on this paradox of schizophrenia
treatment. As we become better at detecting and treat-
ing the core symptoms of schizophrenia, patients have
worsening SMRs. Given the potential for an even
greater disease burden as a result of the introduction
of second-generation antipsychotic medications,
research aimed at optimizing the physical health of
people with schizophrenia needs to be undertaken
with a sense of urgency.
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